Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CRISPR01:59

CRISPR

59.1K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
59.1K
CRISPR01:59

CRISPR

18.9K
18.9K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

2.6K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
2.6K
What is Genetic Engineering?00:49

What is Genetic Engineering?

81.3K
Overview
81.3K
CRISPR and crRNAs02:53

CRISPR and crRNAs

19.5K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
19.5K
Homologous Recombination02:31

Homologous Recombination

65.4K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
65.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GATSBI: improving context-aware protein embeddings through biologically motivated data splits.

Bioinformatics (Oxford, England)·2026
Same author

SOX10 in Mohs for Melanoma: How We Do It.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

TikTok is a valuable data source for tracking the opioid crisis.

NPJ digital medicine·2026
Same author

Drug-Target Interaction Prediction with PIGLET.

bioRxiv : the preprint server for biology·2026
Same author

GATSBI: Improving context-aware protein embeddings through biologically motivated data splits.

bioRxiv : the preprint server for biology·2026
Same author

Biological data governance in an age of AI.

Science (New York, N.Y.)·2026

Related Experiment Video

Updated: Mar 29, 2026

Genome Editing in Mammalian Cell Lines using CRISPR-Cas
07:56

Genome Editing in Mammalian Cell Lines using CRISPR-Cas

Published on: April 11, 2019

23.5K

Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework.

Niklaus H Evitt1, Shamik Mascharak1, Russ B Altman1

  • 1a Stanford University.

The American Journal of Bioethics : AJOB
|December 4, 2015
PubMed
Summary
This summary is machine-generated.

CRISPR germline editing therapies could eliminate genetic diseases. A proposed regulatory framework addresses safety and ethical concerns for responsible research and development of these powerful gene-editing tools.

Keywords:
CRISPR-Casclinical ethicsgene editinggene therapygenetic diseasegermline modification

More Related Videos

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells
09:04

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Published on: September 25, 2019

8.9K
A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
08:20

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization

Published on: September 2, 2021

4.7K

Related Experiment Videos

Last Updated: Mar 29, 2026

Genome Editing in Mammalian Cell Lines using CRISPR-Cas
07:56

Genome Editing in Mammalian Cell Lines using CRISPR-Cas

Published on: April 11, 2019

23.5K
Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells
09:04

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Published on: September 25, 2019

8.9K
A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
08:20

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization

Published on: September 2, 2021

4.7K

Area of Science:

  • Genetics and Genomics
  • Bioethics
  • Regulatory Science

Background:

  • CRISPR germline editing therapies (CGETs) offer revolutionary potential for eradicating hereditary diseases.
  • Significant ethical, safety, and efficacy debates surround human germline modification, leading to funding restrictions.
  • A lack of clear evaluation pathways hinders CGET research and development.

Purpose of the Study:

  • To propose a comprehensive model regulatory framework for CRISPR germline editing therapies.
  • To guide the responsible research, clinical development, and distribution of CGETs.
  • To address the unique technical and ethical challenges inherent in germline editing.

Main Methods:

  • Leveraging existing legal and regulatory structures.
  • Implementing heightened scrutiny across all stages of CGET development.
  • Integrating ethical considerations and safety evaluations into the regulatory process.

Main Results:

  • A proposed framework designed for rigorous evaluation of CGETs.
  • Enhanced oversight mechanisms tailored to the complexities of germline modification.
  • A pathway for advancing CGETs while upholding safety and ethical standards.

Conclusions:

  • A structured regulatory approach is essential for the responsible advancement of CRISPR germline editing therapies.
  • The proposed framework provides a practical model for navigating the challenges of CGETs.
  • This framework aims to facilitate the potential of CGETs in treating genetic disorders while ensuring public trust and safety.